Phase 2 Eczema Trial, Recruiting NCT07355075 Sponsor: Turn Therapeutics Condition: Eczema
Back to Eczema

Phase 2 Eczema Trial, Recruiting

NCT07355075
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old
  • You are male or female and are considered to be in good general health based on your medical history
  • You have visible eczema on your skin that has been assessed as moderate to severe using standard eczema measurement tools
  • You are able to read, understand, and sign a consent form written in English
  • You are willing and able to attend study visits and apply a product to your skin every day as instructed
  • You agree to use only the product provided by the study on the specific skin areas being tested, for the full length of the study

Who may not be able to join:

  • You are currently pregnant, breastfeeding, or planning to become pregnant during the study
  • You have another skin condition that could affect how the treatment works or how results are measured
  • You have used certain medicines that suppress the immune system — including steroid pills, injections, or creams — within the last 3 weeks
  • You are currently using anti-inflammatory medicines such as steroid creams, ibuprofen, or celecoxib (note: steroid nose or eye drops are allowed)
  • You have applied any medicated product to the test areas of skin within the last 72 hours before joining the study
  • The skin at or near the test areas is damaged or unusual in appearance — for example, due to sunburn, tattoos, scars, or uneven skin tone — in a way that could affect results
  • You have any other health condition that the study doctor believes could put you at risk or affect the reliability of the study (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 9728714371

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Turn Therapeutics
Registry
ClinicalTrials.gov
Start date
11 July 2025
Est. completion
10 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Investigator Global Assessment (IGA) at Week 8

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov